Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19 related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC , the flagship journal of the American College of Cardiology. The research will be simultaneously published with presentations at the European Society of Cardiology Conference 2024 in London. This portfolio of publications, derived from three major trials, significantly advances our understanding of the wide-ranging benefits of GLP-1 agonists, while also highlighting key questions that remain.
These groundbreaking medications are poised to revolutionize cardiovascular care and could dramatically enhance cardiovascular health." Harlan Krumholz, MD, FACC, JACC Editor-in-Chief and Harold H. Hines Jr Professor of Medicine, Yale University School of Medicine Semaglutide improves CV outcomes regardless of sex, reduces COVID-19 related death in patients with obesity and CVD In two new substudies of the SELECT Trial, which included people who had overweight or obesity according to BMI and had established cardiovascular disease but not diabetes, researchers looked at whether once weekly semaglutide (2.
4mg) reduced rates of all-cause death, CV death and non-CV death, including death from COVID-19, and whether sex impacts the efficacy and safety of the drug In the mortality.